Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).

Aggarwal, Rahul Raj, Vuky, Jacqueline, VanderWeele, David James · Journal of Clinical Oncology · 2022